Grants and Contributions

Participation in the Canadian medical biotechnology co-innovation mission to the Eureka Global Innovation Summit and Swiss Biotech Day in Switzerland – May 3 to 8, 2026.
Through this mission, BioAro proposes to showcase its technologies to the Swiss Pharma market specifically focusing on the use of PanOmiQ & Genolio for drug discovery and repurposing of existing drugs besides identifying novel targets, thrugh a multi-OMICS approach. The following sectors are being targeted through this mission, for collaborations and identification of partners for Eureka submissions:

The Firm's primary goal for the project is to co-develop and validate a next-generation, AI-powered multi-omics platform that sets new standards for speed, accuracy, and clinical utility.

BioAro is a Canadian AI-Biotech developing AI-guided Precision Medicine through multi-OMICS data analysis, including whole genome (WGS), exome (WES) & microbiome sequencing, cell-free DNA testing, epigenetics & transcriptomics. BioAro’s proprietary AI-driven analytics platform, PanOmiQ, processes this high-dimensional multi-OMICS data for actionable clinical output. These have helped commercialize the BioSport (high performance athletes), BioMYND (mental health) & Biogut (gut wellness & nutrition) programs. BioAro is currently focusing on Drug Development & Discovery, Drug Repurposing & Pharmacogenomics, including in-silico drug design & simulation of clinical trials. BioAro has also built a high performance computing centre

Through the application of national and local priorities, the CSJ program seeks to provide youth, particularly those who face barriers to employment with access to work opportunities. Funded employers must demonstrate that they are providing quality work experiences for youth that provide opportunities to develop and improve their skills.

BioAro is a Calgary-based Canadian SME, joining the smart materials co-innovation mission (Tokyo, from Jan 27-31, 2025) to explore collaborations to develop smart materials (e.g. nanomaterials, piezo materials etc.), for real-time monitoring of vital human functions.

BioAro is developing an AI-guided software platform (PanOmiQ) for end-to-end analysis of Genomic (WGS, WES) and Microbiome (Gut, skin, vaginal, oral) data for precision health support to patients with chronic diseases (cancers, cardiac, IBD etc.). The current project would assist testing, validation and (ML-guided) training of the PanOmiQ software for clinical deployment in hospitals and for use by researchers in academic institutions.

The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.

Development of a Digital Health platform for patient triaging, analysis and correlation of gut microbiome and mental health diseases.

BioAro has embarked on the development of a proprietary PANOMICS (genomics) software, in collaboration with experts from University of Lethbridge, Mount Royal University & AMII. The software shall analyze raw genomic data, clean it, align it with existing databases & identify Pathogenic, Likely pathogenic or Variants of unknown certainty (VUS) genetic alterations & create a clinical association with various diseases/phenotypes. The software shall identify inheritance patterns & provide surveillance of genetic alterations as new clinical research become available. It will integrate Gen/OMIC data with imaging, blood biochemistry & clinical data to provide precise & personalized diagnostic & therapeutic management of patients.